SynAct Pharma AB’s business model is to drive projects into clinical development in order to secure proof-of-concept, i.e. support for clinical relevance. The company‚Äôs ambition is to conduct several Phase II studies, and then enter into commercial agreements with one or more major pharmaceutical companies.